Literature DB >> 1580866

Monoclonal large granular lymphocyte proliferation in SLE with HTLV-I seroreactivity.

P Marlton1, K Taylor, S Elliott, J McCormack.   

Abstract

A 60-year-old part Aboriginal woman was observed to develop severe neutropenia and a large granular lymphocyte (LGL) proliferation five years after the diagnosis of systemic lupus erythematosus (SLE). Monoclonality of the CD3+, CD4-, CD8+ LGL population was confirmed using the novel approach of X-linked restriction fragment length polymorphism (RFLP) analysis. Indeterminate HTLV-I serology was present. The patient responded to steroid therapy. LGL proliferation in the setting of SLE and the use of X-linked RFLP analysis to define LGL clonality have not previously been reported.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580866     DOI: 10.1111/j.1445-5994.1992.tb01711.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  4 in total

1.  Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.

Authors:  Susan Bell Nyland; Daniel J Krissinger; Michael J Clemente; Rosalyn B Irby; Kendall Thomas Baab; Nancy Ruth Jarbadan; Lubomir Sokol; Eric Schaefer; Jason Liao; David Cuthbertson; Pearlie Epling-Burnette; Ronald Paquette; Alan F List; Jaroslaw P Maciejewski; Thomas P Loughran
Journal:  Leuk Res       Date:  2012-03-02       Impact factor: 3.156

2.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 3.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

Review 4.  Persistent Large Granular Lymphocyte Clonal Expansions: "The Root of Many Evils"-And of Some Goodness.

Authors:  Carlos Bravo-Pérez; Salvador Carrillo-Tornel; Esmeralda García-Torralba; Andrés Jerez
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.